Detalles de la búsqueda
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462870
2.
Combination of radiation therapy for brain metastasis and anti-PD-1/PD-L1 treatment in non-small cell lung cancer: two cases and review of the literature.
Anticancer Drugs
; 32(4): 460-464, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33587349
3.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474768
4.
Long-term therapy with Bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature.
Anticancer Drugs
; 31(7): 754-757, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32697470
5.
Biological effects of verbascoside and its anti-inflammatory activity on oral mucositis: a review of the literature.
Anticancer Drugs
; 31(1): 1-5, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31609769
6.
Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma: a case report and review of the literature.
Anticancer Drugs
; 30(4): 425-427, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30640790
7.
Long-term therapy with bevacizumab in a young patient affected by NF-2: a case report and review of the literature.
Anticancer Drugs
; 30(3): 318-321, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30640792
8.
Acquired resistance in oncogene-addicted non-small-cell lung cancer.
Future Oncol
; 14(13s): 29-40, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29989451
9.
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
Future Oncol
; 14(4): 353-361, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29135281
10.
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.
Radiol Oncol
; 47(1): 57-62, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23450278
11.
The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours.
Eur J Cancer
; 187: 134-143, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163806
12.
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
J Hematol Oncol
; 15(1): 9, 2022 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35062993
13.
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Eur J Cancer
; 150: 224-231, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33934059
14.
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
J Immunother Cancer
; 9(4)2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33827906
15.
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Eur J Cancer
; 142: 18-28, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33212418
16.
[Extraperitoneal rectal cancer: chemo-radiotherapy treatments]. / Carcinoma del retto sottoperitoneale: trattamenti chemio/radioterapici perioperatori.
Ann Ital Chir
; 81(4): 247-54; discussion 283, 2010.
Artículo
en Italiano
| MEDLINE | ID: mdl-21322269
17.
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.
Cancers (Basel)
; 12(5)2020 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-32365882
18.
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
Clin Lung Cancer
; 21(6): e567-e571, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32591311
19.
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Clin Lung Cancer
; 21(6): 498-508.e2, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32680806
20.
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Eur J Cancer
; 134: 19-28, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32454395